Fig 2: Activation of the mTORC1 pathway in the striatum following daily oral dosing of NV-5297.(A) Representative immunoblots of the striatum for normalized phosphorylated S6 [S240/244pS6], S6, phosphorylated Akt [S437pAkt], Akt, phosphorylated mTOR [S2448pmTOR], mTOR, DARPP-32, phosphorylated 4E-BP1 [Thr37/46p4E-BP1], 4E-BP1 and Actin from homogenized striatum isolated from N171-82Q males after 6 weeks of daily oral dosing of NV-5297 (160 mg/kg) or vehicle [Veh]. (B) Quantification of the immunoblots from homogenized striatum isolated 1 hour after the final oral dosing with NV-5297 (160 mg/kg; n = 14) normalized to loading control levels and further normalized to vehicle treated mice (n = 15). A significant Spearman correlation is present between pS6/S6 and DARPP32 levels. Data are presented as mean ± SEM. *P = 0.05, ***P = 0.001, ****P = 0.0001 (one-tailed unpaired Student’s t-test [pmTOR/mTOR, DARPP-32], with a Welch’s correction [pS6/S6, p4E-BP1/4E-BP1], Mann-Whitney test [pAkt/Akt].